持续非卧床腹膜透析中促红细胞生成素：皮下注射的经验

Erythropoietin in continuous ambulatory peritoneal dialysis: experience with subcutaneous administration.

作者信息

Eisele G, Bailie G R, Clement C, Wong E

机构信息

Albany College of Pharmacy, New York 12208.

出版信息

Perit Dial Int. 1992;12(1):34-6.

PMID:1543777

Abstract

Experience in the use of subcutaneous erythropoietin (EPO) in 32 continuous ambulatory peritoneal dialysis (CAPD) patients is presented. All patients were treated with oral iron supplements. The total and mean +/- SD durations of EPO treatment were 466 weeks and 14.6 +/- 10.1 weeks respectively. Twenty-two patients started treatment with normal or elevated iron stores; 10 had an initial iron saturation less than 20%. The initial hematocrit was 23.8 +/- 3.7%. Thirteen patients reached a steady-state hematocrit by the end of the study period, when the mean +/- SD hematocrit for all 32 patients was 34.1 +/- 3.6%. All patients responded to EPO. The initial dose of EPO was 147.1 +/- 53.8 U/kg/week. Maintenance dose was 72 +/- 36 U/kg/week.

摘要

本文介绍了32例持续性非卧床腹膜透析（CAPD）患者使用皮下促红细胞生成素（EPO）的经验。所有患者均接受口服铁剂补充治疗。EPO治疗的总时长和平均±标准差时长分别为466周和14.6±10.1周。22例患者开始治疗时铁储备正常或升高；10例患者初始铁饱和度低于20%。初始血细胞比容为23.8±3.7%。13例患者在研究期末达到稳定状态血细胞比容，此时所有32例患者的平均±标准差血细胞比容为34.1±3.6%。所有患者对EPO均有反应。EPO初始剂量为147.1±53.8 U/kg/周。维持剂量为72±36 U/kg/周。